Aggarwal and Associates Limited

Brampton, Ontario L6T OG1

2 studies enrolling now · 24 studies all time

What they study most

Arthritis, Autoimmune Diseases, Body Weight, Connective Tissue Diseases, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias, Immune System Diseases, Joint Diseases

Studies at this site

• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) — Recruiting now
• A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine — Recruiting now
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes — Completed
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight — Completed
• Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications — Completed
• Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use — Completed
• Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) — Running, not enrolling
• Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. — Running, not enrolling
• Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens — Completed
• A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis — Stopped early
• A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time — Completed
• A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity — Completed
• Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity — Stopped early
• 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants — Completed
• Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis — Completed
• A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) — Completed
• A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus — Completed
• A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus — Completed
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis — Completed
• Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee — Completed
• Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain — Completed
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) — Completed
• A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin — Completed
• Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin — Completed